Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Airdoc Technology Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.30.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.29.
During the past 3 years, the average EBIT per Share Growth Rate was 50.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Beijing Airdoc Technology Co's EBIT per Share or its related term are showing as below:
HKSE:02251'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -65.7 Med: -21.7 Max: 50.8
Current: 50.8
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Beijing Airdoc Technology Co was 50.80% per year. The lowest was -65.70% per year. And the median was -21.70% per year.
HKSE:02251's 3-Year EBIT Growth Rate is ranked better than 87.24% of 525
companies
in the Healthcare Providers & Services industry
Industry Median: 11.7
vs HKSE:02251: 50.80
Beijing Airdoc Technology Co (HKSE:02251) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Beijing Airdoc Technology Co EBIT per Share Related Terms
Beijing Airdoc Technology Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Airdoc Technology Co (HKSE:02251) has a EBIT per Share of HK$-0.29 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Beijing Airdoc Technology Co and its competitors. According to the industry distribution chart, Beijing Airdoc Technology Co ranks #67 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 12.8%.
Is Beijing Airdoc Technology Co's EBIT per Share too high?
Beijing Airdoc Technology Co's current EBIT per Share is HK$-0.29. Based on the distribution chart, Beijing Airdoc Technology Co ranks #67 out of 525 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Airdoc Technology Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Airdoc Technology Co's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Beijing Airdoc Technology Co ranks #67 out of 525 companies for EBIT per Share. This places Beijing Airdoc Technology Co in the top 13% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.70, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Beijing Airdoc Technology Co and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Airdoc Technology Co's current EBIT per Share is HK$-0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Airdoc Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co (HKSE:02251) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$15.19, compared to a current price of HK$9.00 — trading 40.8% below its estimated fair value. The current EBIT per Share is HK$-0.29. Beijing Airdoc Technology Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Beijing Airdoc Technology Co (HKSE:02251), the current EBIT per Share is HK$-0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Airdoc Technology Co (HKSE:02251) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Airdoc Technology Co stock appears to be undervalued.
The current stock price of HK$9.00 is trading 40.8% below its estimated GF Value™ of HK$15.19.
GuruFocus considers Beijing Airdoc Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02251:
EBIT per Share: HK$-0.29
GF Value™: HK$15.19 vs. price of HK$9.00 (40.8% below fair value)
No single metric tells the full story. See the HKSE:02251 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
64GF Score
Get the complete analysis for HKSE:02251
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02251 has been successfully added to your 
